EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparing the pharmacological effects of different ginsenosides in rodent models of heart failure: a systematic review and network meta-analysis

Vergleich der pharmakologischen Effekte verschiedener Ginsenoside in Nagetiermodellen der Herzinsuffizienz: systematische Übersicht und Netzwerk-Metaanalyse

Chang Su, Peng Tian, Bo Chen, Kun Lian, Zizheng Wu, Lifa Wu, Weijun Li, Zhixi Hu

Frontiers in Pharmacology · 11.11.2026 · 17

DOI: 10.3389/fphar.2026.1939723 ↗

Auf einen Blick

29 Studien zeigen in Tiermodellen der Herzinsuffizienz für mehrere Ginsenoside Verbesserungen kardialer Funktionsparameter gegenüber den Modellkontrollen. Die Ergebnisse waren je nach Ginsenosid und Endpunkt unterschiedlich.

Fragestellung

Wie unterscheiden sich verschiedene Ginsenoside in ihren Effekten auf hämodynamische und kardiale Funktionsparameter in Tiermodellen der Herzinsuffizienz?

Methode

Systematische Übersicht und Netzwerk-Metaanalyse von Studien zu Rb1, Rg1, Rg3, Rg5 und Totalginsenosiden in Tiermodellen der Herzinsuffizienz; random-effects Analyse mit 95 %-KI und 95 %-PrI; SYRCLE-Risiko-bias.

Ergebnisse

Eingeschlossen wurden 29 Studien mit 10 Ginsenosid-Interventionen. Mehrere Ginsenoside verbesserten LVEF, LVFS, LVEDP, +dP/dtmax und BNP gegenüber Modellkontrollen; HW/BW zeigte keinen signifikanten Effekt.

Einschränkungen

Keine geschlossenen Netzwerke, daher keine Inkonsistenzprüfung; methodische Limitationen der eingeschlossenen Studien; für HW/BW war die Evidenz unzureichend.

Schlussfolgerung der Autor:innen

Einige Ginsenoside verbessern hämodynamische und kardiale Funktionsparameter in Nagetiermodellen der Herzinsuffizienz. Die Befunde müssen in hochwertigen präklinischen Studien bestätigt werden.

Kernaussagen

  • 29 Studien mit 10 Ginsenosid-Interventionen
  • Verbesserungen bei LVEF, LVFS, LVEDP und +dP/dtmax
  • HW/BW: kein signifikanter Effekt; Evidenz unzureichend

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2026. Verfasst von Chang Su und 7 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate and compare the effects and potential advantages of different ginsenosides in animal models of heart failure (HF).

Methods

We systematically searched for and extracted data from studies of ginsenosides, including Rb1, Rg1, Rg3 and Rg5, and total ginsenosides in animal models of HF. Outcomes included left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular end-diastolic pressure (LVEDP), maximum rate of left ventricular pressure rise (+dP/dtmax), serum brain natriuretic peptide (BNP) and the heart weight index. Random-effects network meta-analysis estimated effects relative to model controls, with 95% confidence intervals (CIs) and 95% prediction intervals (PrIs). All networks were star-shaped, sharing the model control as a common comparator, and lacked closed loops; statistical inconsistency testing was therefore not possible. Exploratory analyses examined effect modification by model type, animal species, administration route and treatment duration. Sensitivity analyses included stratification by model type, separate analyses of BNP and NT-proBNP, alternative effect scales for HW/BW, and networks restricted to individual ginsenosides. Study quality was assessed using the SYRCLE risk-of-bias tool. The study sought to compare the pharmacological profiles of individual ginsenosides and provide evidence to inform intervention selection for clinical trials in HF.

Results

We included 29 studies covering 10 ginsenoside interventions. Several ginsenosides significantly improved cardiac functional outcomes compared with HF model controls. For serum BNP reduction, Rg1 (SMD = −2.38, 95% CI -4.51 to −0.25), Rb1 (SMD = −2.60, 95% CI -3.80 to −1.40) and total ginsenosides (SMD = −1.94, 95% CI -3.07 to −0.82) showed significant effects. However, the Rg1 effect was no longer significant after mixture nodes were excluded. Significant increases in LVEF were observed with total ginsenosides (MD = 17.56, 95% CI 7.65–27.48), Re (MD = 17.31, 95% CI 2.16–32.46), Rg3 (MD = 16.09, 95% CI 6.03–26.14), Rb1 (MD = 12.09, 95% CI 6.71–17.46) and Rg1 (MD = 13.68, 95% CI 3.28–24.09). LVFS was significantly higher with Rg1 (MD = 11.72, 95% CI 4.92–18.52), Rg3 (MD = 9.90, 95% CI 5.50–14.29), total secondary ginsenosides (MD = 10.30, 95% CI 2.12–18.48), Rb1 (MD = 8.95, 95% CI 6.16–11.74),Re (MD = 8.29, 95% CI 0.24–16.34) and Rd (MD = 6.48, 95% CI 0.45–12.51). Total ginsenosides (MD = −3.97, 95% CI -4.39 to −3.55), Re (MD = −1.65, 95% CI -2.24 to −1.06), Rb1 (MD = −1.49, 95% CI -2.54 to −0.44) and Rb2 (MD = −1.40, 95% CI -2.48 to −0.32) significantly reduced LVEDP. Total ginsenosides (MD = 1374.00, 95% CI 425.00–2,323.00) and Rb1 (MD = 1200.74, 95% CI 718.89–1682.60) significantly increased +dP/dtmax. For the heart weight-to-body weight (HW/BW) ratio, none of the five nodes (Rh2, Rb1, Rg5, Re and Rg1) showed a significant effect (all P > 0.05). The available evidence was insufficient to determine the effects of ginsenosides on HW/BW.

Conclusion

Some ginsenosides improve haemodynamic and cardiac functional outcomes in rodent models of HF. Given the methodological limitations of the included studies, these findings require confirmation in high-quality preclinical studies. Systematic review registration https://osf.io/ye48s/ ; Identifier, YE48S

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Su, C., Tian, P., Chen, B., Lian, K., Wu, Z., Wu, L., Li, W., & Hu, Z. (2026). Comparing the pharmacological effects of different ginsenosides in rodent models of heart failure: a systematic review and network meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1939723

Vancouver

Su C, Tian P, Chen B, Lian K, Wu Z, Wu L, et al. Comparing the pharmacological effects of different ginsenosides in rodent models of heart failure: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1939723

BibTeX
@article{Su2026,
  author = {Su, Chang and Tian, Peng and Chen, Bo and Lian, Kun and Wu, Zizheng and Wu, Lifa and Li, Weijun and Hu, Zhixi},
  title = {Comparing the pharmacological effects of different ginsenosides in rodent models of heart failure: a systematic review and network meta-analysis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1939723}
}
Kostenlos starten →